Outcomes-based contracting in the US pharmaceutical market

$19.99

Outcomes-based contracting in the US pharmaceutical market

Category:
Description

Outcomes-based contracting in the US pharmaceutical market

Slides in the pack:

  1. An introduction to outcomes-based contracting
  2. Payers are looking for outcomes-based contracting in various therapeutic areas
  3. History of outcomes-based contracting in the US
  4. Outcomes-based contracts recently announced in the US
  5. In 2015, Amgen negotiated its first pay-for-performance deal with Harvard Pilgrim for Repatha
  6. In 2017, Amgen negotiated another outcomes-based contract with Harvard Pilgrim for Enbrel
  7. Types of pharmaceutical outcomes-based contracts
  8. Pre-conditions for the implementation of outcomes-based contracts
  9. Benefits and challenges associated with outcomes-based contracts

 

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Outcomes-based contracting in the US pharmaceutical market”

Your email address will not be published. Required fields are marked *